{"title":"An Overview of the Anticoagulant Drugs Used in Routine Clinical Practice","authors":"N. Vene, A. Mavri","doi":"10.5772/INTECHOPEN.76206","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.76206","url":null,"abstract":"Anticoagulant drugs directly or indirectly influence coagulation factors preventing fibrin formation thus preventing blot clotting. They are classified into two groups according to the mode of application, namely parenteral and oral drugs. Among the latter, vitamin K antagonists (most often warfarin) were the only available oral drugs and were widely used for almost a century. In the recent years, new oral anticoagulant drugs became available that directly target either factor IIa or Xa. This chapter provides an overview of both parenteral and oral anticoagulant drugs used in clinical practice with description of the mode of action and management of therapy in different clinical settings.","PeriodicalId":358690,"journal":{"name":"Anticoagulant Drugs","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127341838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-World Safety of Anticoagulants","authors":"N. Lombardi, G. Crescioli, A. Vannacci","doi":"10.5772/INTECHOPEN.78023","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.78023","url":null,"abstract":"The aim of the present chapter is to characterize the management of anticoagulation in the real-world clinical setting, describing all pharmacological aspects of anticoagulant medications, in particular safety aspects. The chapter is structured into three main sections. Within the first two sections, active principles are classified on the basis of their pharmacological properties (pharmacodynamic and pharmacokinetic characteristic) in old and new molecules (or first and second generation class). In the third one, we discuss safety issues of anticoagulants using available data from postmarketing evidences. Furthermore, we also provide some essential information on the use of this kind of medications in special populations (i.e., elderly, coronary artery disease, diabetics, chronic kidney disease, etc.) in clinical practice.","PeriodicalId":358690,"journal":{"name":"Anticoagulant Drugs","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116164066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"FXa Direct Synthetic Inhibitors","authors":"Flavia C. Zacconi","doi":"10.5772/INTECHOPEN.76518","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.76518","url":null,"abstract":"Factor Xa (FXa) is an enzyme belonging to the serine protease family which plays a vital role in hemostasis, being an essential part in the blood-clotting cascade by catalyzing the thrombin and clot production, and wound closure. Moreover, the improvement of new anticoagulants drugs is essential to prevent cardiovascular thrombotic and pathologies. FXa has been a main target for the design of new drugs with important antithrombotic action; nevertheless direct FXa inhibitors that are available still have side effects and drawbacks. This chapter describes the FXa function in the blood-clotting cascade, the molecular and structural characteristics of this essential enzyme, and the novel FXa synthetic drug characteristics. This chapter highlights the importance of continuing the efforts towards searching and designing novel and safer anticoagulant drugs.","PeriodicalId":358690,"journal":{"name":"Anticoagulant Drugs","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125062999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anticoagulation for Atrial Fibrillation in Patients with End- Stage Kidney Disease","authors":"Q. Tran, Bassim Jebeili, K. Sud, Bhadran Bose","doi":"10.5772/INTECHOPEN.78022","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.78022","url":null,"abstract":"Atrial fibrillation (AF) is common in patients with kidney disease, with prevalence several times greater than in the general population. Anticoagulation agents are used to prevent thromboembolic events as a consequence of AF. Several randomized trials have established the efficacy of antithrombotic drugs for preventing stroke in patients with AF, with both antiplatelet agents and oral anticoagulants showing benefit. End- stage kidney disease (ESKD) patients have known platelet defects/dysfunction and also receive heparin during their dialysis treatment, which contributes to their overall coagu- lopathy. Warfarin being vitamin-K antagonist can augment calciphylaxis in patients with ESKD. Taken together, formal anticoagulation use in patients with ESKD may confer additional risk that is not appreciated in patients without kidney disease. In particular, patients on new oral anticoagulants show excess morbidity and mortality from bleeding when compared to warfarin. RE-LY study the first open label study to compare dabigatran, a direct thrombin inhibitor, to warfarin in patients with one or more risk factors for stroke The a higher dose (110 and 150 twice daily) of dabigatran was superior to warfarin in reducing and systemic embolism. The study revealed the effect of creatinine clearance and renal function on dabigatran’s action and pharmacokinetics. Dabigatran is highly dependent on excretion with 80% being excreted unchanged in the A 20% of in RE-LY mL/min CrCl mL/min RE-LY Large-scale trials for use in CKD dabigatran dialysis, anticoagulation HD Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin-K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial— examined rivaroxaban versus warfarin in patients with two or more risk factors for a stroke. The study showed that rivaroxaban stroke and embolism in ICH. The study show all-cause CrCl mL/min trial,","PeriodicalId":358690,"journal":{"name":"Anticoagulant Drugs","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130106963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Heparin-Induced Thrombocytopenia (HIT)","authors":"M. Tomičić, I. Jukić, A. Hećimović, T. Vuk","doi":"10.5772/INTECHOPEN.78024","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.78024","url":null,"abstract":"Heparin-induced thrombocytopenia (HIT I) is a severe, life-threatening, and immuno- logical drug reaction. According to the clinical-laboratory characteristics, there are two types of HIT: type I (HIT I) and type II (HIT II). HIT I is the result of non-immunologic, direct interaction of heparin with the platelet surface. Contrary, HIT II is immunologically induced (antibody-mediated) and life-threatening side effect of heparin therapy, often associated with thromboembolic complications. All patients receiving heparin are exposed to the development of anti-heparin antibodies, irrespective of the heparin dos- age, type, and method of administration. HIT most commonly develops in intensive care patients, dialyzed patients, and cardiosurgical and orthopedic patients. It commonly develops after 5–10 days of heparin therapy. Platelet count decreases by more than 50% from the baseline and ranges from 20 × 10 9 /L to 100 × 10 9 /L. In HIT II, thromboembolic complications usually include deep-vein thrombosis and pulmonary embolism, but they also include arterial occlusion of the extremities, myocardial infarction, stroke, and necrosis and organ damage. Clinical assessment of the HIT probability using 4T´s score system, systematic monitoring of platelet number in heparin-receiving patients, and specific laboratory diagnosis of anti-heparin antibodies substantially contribute to the final confirmation of the diagnosis, enable timely administration of direct non-heparin thrombin antagonists, and reduce mortality from thromboembolic complications. and method of administration. HIT most commonly develops in intensive care patients, dialyzed patients, and cardiosurgical and orthopedic patients. Clinical assessment of the HIT probability using 4T scoring system, systematic monitoring of platelet number in heparin-receiving patients, and specific laboratory diagnosis of anti-heparin antibodies substantially contribute to the final confirmation of the diagnosis, enable timely administration of direct non-heparin throm bin antagonists, and reduce mortality from thromboembolic complications.","PeriodicalId":358690,"journal":{"name":"Anticoagulant Drugs","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127786371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anticoagulants from Hematophagous","authors":"A. Chudzinski-Tavassi, F. Faria, M. P. A. Flores","doi":"10.5772/INTECHOPEN.78025","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.78025","url":null,"abstract":"This chapter will focus on anticoagulant molecules described until now from hematopha- gous animals. The evolutionary scenario for hematophagous animals is convergent and has resulted on a wide diversity of saliva anticoagulants, substances with platelet anti- aggregation action, and also with vase-dilating action. Hematophagous animals such as bloodsuckers (leeches, mosquitoes, and ticks) have developed strategies that specifically target proteinases from the hemostatic system of the animals they feed, thus keeping the blood incoagulable. The saliva of those animals provides a large amount of molecules to modulate the innate immune response of the host and to inhibit blood coagulation in order to facilitate the feeding. Thus, anticoagulants from hematophagous animals rep- resent a very interesting tool for studies ranging from basic research to applications in the therapeutic area, as anticoagulant medication. Several studies have pointed out that anticoagulants from hematophagous can also display non-hemostatic functions as antitumor, bringing new perspectives for the study of these molecules. The comprehension of the multi-faced physiological roles of those new anticoagulants from hematophagous opens new perspectives for therapeutic and biotechnological approaches.","PeriodicalId":358690,"journal":{"name":"Anticoagulant Drugs","volume":"570 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124146024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}